Tryptophan hydroxylase isoform 2 (TPH2) is expressed in serotonergic neurons in the raphe nuclei, where it catalyzes the rate-limiting step in the synthesis of the neurotransmitter serotonin. In search for functional polymorphisms within the TPH2 gene locus, we measured allele-specific expression of TPH2 mRNA in sections of human pons containing the dorsal and median raphe nuclei. Differences in allelic mRNA expression -referred to as allelic expression imbalance (AEI) -are a measure of cis-acting regulation of gene expression and mRNA processing. Two marker SNPs, located in exons 7 and 9 of TPH2 (rs7305115 and rs4290270, respectively), served for quantitative allelic mRNA measurements in pons RNA samples from 27 individuals heterozygous for one or both SNPs. Significant AEI (ranging from 1.2-to 2.5-fold) was detected in 19 out of the 27 samples, implying the presence of cis-acting polymorphisms that differentially affect TPH2 mRNA levels in pons. For individuals heterozygous for both marker SNPs, the results correlated well (r = 0.93), validating the AEI analysis. AEI is tightly associated with the exon 7 marker SNP, in 17 of 18 subjects. Remarkably, expression from the minor allele exceeded that of the major allele in each case, possibly representing a gain-of-function. Genotyping of 20 additional TPH2 SNPs identified a haplotype block of five tightly linked SNPs for which heterozygosity is highly correlated with AEI and overall expression of TPH2 mRNA. These results reveal the presence of a functional cis-acting polymorphism, with high frequency in normal human subjects, resulting in increased TPH2 expression levels. The SNPs that correlate with AEI are closely linked to TPH2 SNPs previously shown to associate with major depression and suicide.
Introduction
Tryptophan hydroxylase (TPH) catalyzes the ratelimiting step in the synthesis of serotonin (5-hydroxytryptamine; 5-HT), 1 a neurotransmitter that plays an important role in the regulation of mood. 2 Dysregulation of serotonergic activity has been associated with major depression, anxiety disorders and suicidal behavior. 3 Most antidepressant drugs, including the serotonin-selective reuptake inhibitors (SSRIs) and many tricyclic antidepressants (TCAs), increase levels of extracellular serotonin by inhibiting its reuptake or blocking its metabolism. Tryptophan hydroxylase 2 (TPH2) is a recently discovered isoform of TPH that is specifically expressed in the brain, with particularly high expression in the serotonergic neurons of the raphe nuclei. [4] [5] [6] The dorsal and median raphe nuclei are the major source of serotonin in the forebrain, 4 including areas implicated in mood and anxiety disorders.
As TPH2 is strategically placed to regulate serotonin levels in the brain, there is currently great interest in identifying genetic variants that affect the level of TPH2 enzymatic activity or control the levels of expression of the TPH2 gene. Extensive DNA sequencing of the TPH2 gene has revealed that polymorphisms that change the amino-acid sequence of the TPH2 protein are rare. [7] [8] [9] The focus of research has therefore, now changed to identifying genetic variants that influence the TPH2 gene expression.
Recently, measurement of mRNA allelic expression imbalance (AEI) has emerged as a powerful method for identifying genetic variants that influence the expression of mRNAs. 10, 11 In this method, relative levels of mRNA expressed from each of two alleles are measured using RNA isolated from individuals who are heterozygous for a marker single nucleotide polymorphism (SNP) within the mRNA. Using this method, it is possible to reliably detect differences in expression levels between alleles as small as 20%. As comparisons between expression levels are made using single samples of RNA isolated from specific organs or tissues, variation between individuals that arise from differences in environmental factors, physiological states, or trans-acting factors are minimized: the mRNA from each allele acts as the control for the other. We have previously used this technique to quantify AEI of mRNAs encoding human H þ / dipeptide transporter 2 (PEPT2), 12 p-glycoprotein (MDR1), 13 the m-opiate receptor (OPRM), 14 and the serotonin transporter (SERT). 15 The goal of this study was to determine whether allele-specific mRNA expression of TPH2 gene occurs and, if so, identify cis-acting genetic elements that predict high or low levels of expression.
Materials and methods

Materials
Frozen sections of rostral pons containing the dorsal and median raphe nuclei from 48 individuals were purchased from the Brain and Tissue Bank for Developmental Disorders (University of Maryland, Baltimore, MD, USA). The demographics of this collection have been described previously. 15 Oligonucleotide primers were designed using the program Oligo 4.0 (National Biosciences Inc., Plymouth, MN, USA) and synthesized by Integrated DNA Technologies (Coralville, IA, USA).
Isolation of DNA and RNA from human pons Isolation of DNA and RNA from the tissue samples in our collection has been described previously. 15 Briefly, frozen sections of pons were incubated in 10 volumes of RNAlater-ICE Frozen Tissue Transition solution (Ambion Inc., Austin, TX, USA) overnight at À801C to maximize recovery of DNA and RNA. The next day, a small piece of tissue from the ventral edge of each sample was removed and homogenized in DNA lysis buffer for isolation of genomic DNA and the remaining portion of the sample homogenized in Trizol reagent (Invitrogen, Carlsbad, CA, USA) for isolation of total RNA.
Genotyping
Genotyping of TPH2 SNPs using SNaPshot primer extension assays was carried out as described previously. 15 Briefly, short (100-300 bp) segments of genomic DNA were Polymerase Chain Reaction (PCR)-amplified using pairs of synthetic oligonucleotide primers that flank each SNP. Following amplification, the unincorporated dNTPs were inactivated with antarctic alkaline phosphatase (New England Biolabs, Ipswich, MA, USA) and excess primers degraded with exonuclease I (New England Biolabs). The PCR products were used as templates in SNaPshot primer extension assays (Applied Biosystems, Foster City, CA, USA), using extension primers designed to anneal to the amplified DNA immediately adjacent to the SNP site. The resulting fluorescently labeled primers were analyzed by capillary electrophoresis using an ABI3730 DNA analysis system and Gene Mapper 3.0 software (Applied Biosystems Inc.). The TPH2 SNPs we examined are listed in Table 1 . The locations of these SNPs within the TPH2 gene are shown in Figure S1 in Supplemental materials (available online). Sequences of the PCR amplification and primer extension primers and reaction conditions for each primer set used for genotyping are available upon request.
LD and haplotype analysis D 0 values for each pair of SNPs and estimated haplotype frequencies were calculated using Haploview (version 3.3; http://www.broad.mit.edu/mpg/ haploview/), 16 Predicted diplotypes for each individual in our collection were calculated from the genotyping data using HelixTree RT (GoldenHelix, Inc., Bozeman, MT, USA).
AEI measurements
Measurements of allele-specific mRNA expression were carried out as described previously. 15 Briefly, RNA from each sample was treated with RNase-Free DNase Set (Qiagen, Valencia, CA, USA) for 15 min and re-isolated using QIAGEN RNeasy columns. Complementary DNA (cDNA) was generated from 1 mg RNA in 20 ml reaction mixes containing 1 ml (200 U) Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA), 1 ml of 50 mM oligo(dT) 20 primer (Invitrogen), 1 ml of 10 mM dNTP mix (Invitrogen), 0.5 ml of 1 mM TPH2 gene-specific primer (5 0 -TTAATTCTCCAATGGAGGAAAGGA-3 0 ), 4 ml of 5 Â first-strand buffer (Invitrogen), 1 ml of RNaseOUT (40 U/ml), and RNase-free water. A cDNA segment containing marker SNPs rs7305115 and rs4290270 was amplified using Taq DNA polymerase (Promega, Madison, WI, USA), the forward primer 5 0 -ACGA GACTTTCTGGCAGGACTG-3 0 , and the reverse primer 5 0 -TTAATTCTCCAATGGAGG-AAAGGA-3 0 with the following cycles: (1 Â (5 min at 951C); 35 Â (30 s at 951C, 30 s at 601C, 1 min at 721C) 1 Â (7 min at 721C)). Following amplification, the unincorporated dNTPs were inactivated with antarctic alkaline phosphatase (New England Biolabs) and excess primers degraded with exonuclease I (New England Biolabs). SNaPshot Primer extension assays were carried out using the extension primer 5 0 -GATCCCCTCTACACCCC-3 0 for rs7305115 and 5 0 -AAAGGAGTCCTGCTCCATA-3 0 for rs4290270 with the following cycles: (25 Â (10 s at 961C, 5 s at 501C, 30 s at 721C)). Unincorporated fluorescent dNTP analogs were removed by incubation with 1.0 U of intestinal calf phosphatase (10 000 U/ml; New England Biolab) for 3 h at 371C. The primer extension products were resolved by capillary electrophoresis using an Applied Biosystems 3730 DNA Analyzer and quantified using the Gene Mapper 3.0 software (Applied Biosystems).
Addition of different fluorescently labeled dideoxynucleotides onto the 3 0 -end of the primers produces oligonucleotides with slightly different electrophoretic mobilities and distinct fluorescence spectra. As different fluorophores differentially affect the efficiency of nucleotide incorporation and have different fluorescence yields, peak area ratios of genomic DNA diverge from the theoretical ratio of 1.0. The measured ratios for genomic DNA were therefore normalized to 1.0 by multiplying each measured ratio by the inverse of the mean of the genomic DNA ratios (correction factor = 1/(mean of measured genomic DNA ratios)). Two tissue samples (no. 1230 and no. 1609) yielded allelic DNA ratios significantly different from the mean ( > 4 s.d., indicating the presence of a gene dosage effect), and were excluded from the calculated mean DNA ratios. RNA (i.e., cDNA) ratios from heterozygous samples were multiplied by the same correction factor. SNaPshot assays were performed 3 Â with genomic DNA and 3 Â with three independent cDNA preparations per sample.
Real-time PCR TPH2 and glyceraldehydes-3-phosphate dehydrogenase (GAPDH) mRNA levels were measured by realtime PCR using an ABI 7000 DNA sequence detection system (Applied Biosystems, Foster City, CA, USA) as previously described. 15 Briefly, TPH2 or GAPDH cDNA was synthesized from 1 mg total pons RNA using reverse-transcriptase and the primers:
(GAPDH). Segments of TPH2 or GAPDH cDNAs were amplified using TPH2-or GAPDH-specific primer sets and heatactivated Taq DNA polymerase in reaction mixes containing dNTPs, buffer, SYBR-Green and a reference dye (Applied Biosystems, Foster City, CA, USA). The TPH2 amplification primers were: 5 0 -ACGA GACTTTCTGGCAGGACTG-3 0 (forward) and 5 0 -TT AATTCTCCAATGGAGGAAAGGA-3 0 (reverse) and the GAPDH amplification primers were: 5 0 -CAGCAA GAGCACAAGAGGAAGAGAGA-3 0 (forward) and 5 0 -GTGTGGTGGGGGACT-GAGTGTG-3 0 (reverse). Amplification conditions consisted of a 10-min preincubation at 951C to activate the Taq DNA polymerase, followed by 40 cycles of denaturation at 951C for 15 s and primer annealing and extension for 1 min at 601C. PCR product melting curves were examined to confirm the homogeneity of PCR products. TPH2 mRNA measurements were expressed as cycle thresholds (C T ) and normalized by subtracting C T values obtained with GAPDH mRNA.
Statistics
Differences between corrected genomic and mRNA (cDNA) ratios were tested for statistical significance using the General Linear Model (GLM) procedure in SAS (SAS Institute Inc., Cary, NC, USA). Agreement between AEI measurements using the marker SNP rs7305115 or rs4290270 was assessed by calculating the Pearson correlation coefficient for mean AEI values for individuals heterozygous for both SNPs (n = 13). Correlations between heterozygosity of TPH2 SNPs and AEI of THP2 mRNA were examined by calculating Kappa-coefficients using SPSS (SPSS Inc., Chicago, IL, USA). Agreement was defined to be either heterozygous and TPH2 AEI > 1.2, or homozygous with TPH2 AEI < 1.2. Exact two-sided P-values for the significance of the kappa estimate were computed.
Results
To identify samples suitable for TPH2 mRNA AEI measurements, we genotyped chromosomal DNA from each of our samples for two marker SNPs: rs7305115 (exon 7) and rs4290270 (exon 9). (See Figure S1 in Supplemental materials for the locations of these and additional TPH2 SNPs.) Among the 48 individuals in our collection, 18 were heterozygous for rs7305115 (G/A) and 22 Figure 1 shows the results of mRNA AEI measurements for the 18 individuals heterozygous for rs7305115. Seventeen of the samples (94%) showed higher expression of mRNA for the A-allele compared to the G-allele, with ratios ranging from 1.2 to 2.5 ( Table 2 ). The G-allele represents the reference sample (wild-type), while the A-allele is a minor, albeit frequent, variant. Sample 1540 showed no significant AEI. All but two of the samples yielded allelic ratios for genomic DNA close to the expected value of 1.0. Two samples (no. 1230 and no. 1609) consistently yielded ratios significantly below 1.0. These low ratios suggest a possible duplication in the TPH2 locus containing the G-allele. Figure 2 shows the results of AEI assays for the 22 individuals heterozygous for rs4290270. There was significant AEI in 13 RNA samples, with higher expression of the T-allele (again the frequent minor variant). Ratios ranged from 1.2 to 2.5 ( Table 2) . Thirteen of the 22 samples were heterozygous for both marker SNPs, affording the opportunity to validate the results obtained with the marker SNP rs7305115. Figure 3 shows that there is an excellent correlation between AEI measurements made using the two marker SNPs.
The results in Figures 1-3 show that heterozygosity of rs7305115 is highly correlated with TPH2 mRNA AEI (17/18 = 94%), while heterozygosity of rs4290270 is less highly correlated (13/22 = 59%). These results raise the possibility that rs7305115 is tightly linked to the 'functional' polymorphism that controls levels of TPH2 mRNA expression, or is itself a functional polymorphism.
To determine whether additional SNPs correlate with TPH2 mRNA AEI, we genotyped 20 additional common TPH2 SNPs. (See Table 1 and Figure S1 in Supplemental materials for allele frequencies and locations of these SNPs.) Alleles of each of the SNPs were in Hardy-Weinberg equilibrium in our population (not shown). Figure S2A shows a linkage disequilibrium (LD) (D 0 ) plot for each pair of SNPs, which was constructed from the genotyping data for the 36 Caucasians in our sample. These data show that TPH2 comprises four haplotype blocks: the first contains SNPs rs4570625 to rs2129575, the second rs1386488 to rs1352251, the third rs1473473 to rs9325202, and the fourth rs1487275 to rs1352252. These results are in close agreement with the haplotype structure determined from previous studies of Caucasian subjects: the HapMap CEU collection (http://www.hapmap.org/; Figure S1 ) and US and Figure 1 Comparison of genomic DNA and mRNA (cDNA) ratios assayed using the marker SNP rs7305115. Data are expressed as ratios of A:G alleles, corrected as described in Materials and methods. The lightly shaded bars represent the average of three DNA ratio measurements using three independent preparations of pons genomic DNA. The darkly shaded bars represent the average of three mRNA ratio measurements using three independent cDNA preparations from a single preparation of pons total RNA. The error bars indicate (7) s.d. for each set of measurements. Samples where the mRNA ratios are statistically different from 1.0 (P < 0.001) using the GLM procedure in SAS are marked with an asterisk (*). Two genomic DNA samples (no. 1230 and no. 1609) that yielded AEI ratio significantly < 1.0 are marked with arrowheads. Figure 2 Comparison of corrected genomic DNA and mRNA (cDNA) ratios assayed using the marker SNP rs4290270. Data are expressed as ratios of T:A alleles, as described in Materials and methods. The lightly shaded bars represent the average of three DNA ratio measurements using three independent preparation of pons genomic DNA. The darkly shaded bars represent the average of three mRNA ratio measurements using three independent cDNA preparations from a single preparation of pons total RNA. The error bars indicate (7) s.d. for each set of measurements Samples where the mRNA ratios are statistically different from 1.0 (P < 0.001) using the GLM procedure in SAS are marked with an asterisk (*).
Finnish populations. 17 The frequencies of haplotypes within each block are listed in Figure S2B , and the predicted diplotypes for each individual in our collection are listed in Table S1 in Supplemental materials.
The possible contribution of each SNP to TPH2 mRNA AEI was evaluated by looking for correlations between heterozygosity/homozygosity of the SNP and the presence/absence of AEI for TPH2 mRNA within the 27 samples where AEI measurements were made. A tabulation of these results is shown in Table S2 in Supplemental materials. The strength of each correlation was assessed using the Kappa-statistic. 18 As shown in Figure 4 , five closely linked SNPs, rs2171363 (C/T), rs4760815 (T/A), rs7305115 (G/A), rs6582078 (T/G), and rs9325202 (G/A), showed statistically significant correlations with TPH2 mRNA AEI (Kappa-coefficients > 0.66). Heterozygosity of rs1352251 (T/C) also correlated with TPH2 mRNA AEI (Kappa-coefficient = 0.534). An independent test using a decision-tree-based algorithm (Helix-Tree RT ) found significant statistically correlations between SNP heterozygosity and AEI (P < 0.01) for rs2171363, rs4760815, rs7305115, rs6582078 and rs9325202 (data not shown).
As mentioned above, AEI measurements revealed that TPH2 mRNA containing the rs7305115 A-allele is expressed at higher levels than mRNA containing the G-allele. Among 18 samples showing AEI for TPH2 mRNA, 17 were heterozygous for rs7305115 (Table  S1 ). Fifteen of the 18 samples were heterozygous for the exact complementary (i.e., 'yin' and 'yang') haplotypes CTGTG and TAAGA, comprising the SNPs rs2171363, rs4760815, rs7305115, rs6582078, and rs9325202, respectively. Table 3 lists the frequencies for haplotypes containing the rs7305115 G-allele or A-allele within the Caucasian subset of our sample. These data show that G-allele haplotypes, which are associated with low TPH2 mRNA expression, are more common (0.6) than A-allele haplotypes (0.4), rs4570625  rs10748185  rs2129575  rs1386488  rs1843809  rs1386495  rs1386494  rs6582072  rs2171363  rs4760815  rs7305115  rs6582078  rs1023990  rs1007023  rs13522   51  rs1473473  rs93252   02  rs1487275   rs1386  486  rs429027  0  rs18728  24  rs13522 52 * * * * * * * * * * Figure 4 Correlations between heterozygosity of individual TPH2 SNPs and AEI of TPH2 mRNA. Y-axis: Kappa-coefficients were calculated from the data in Table S4 which are associated with high TPH2 mRNA expression. The population frequencies of the rs7305115 G-and A-alleles are similar to those previously reported for Caucasian populations ((http://www. ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs = 7305115) and Zhm et al. 17 ). To test our ability to predict levels of TPH2 mRNA expression based upon genotype, we compared levels of TPH2 mRNA in pons samples from individuals who are heterozygous (G/A) or homozygous (G/G or A/A) for rs7305115 alleles. Real-time reverse transcriptase (RT)-PCR measurements of TPH2 mRNA were carried out using RNA isolated from 18 (G/G), 21 (G/A) and nine (A/A) samples. TPH2 mRNA measurements (expressed as C T ) were normalized by subtracting C T values for GAPDH mRNA, which is ubiquitously expressed. Pairwise comparisons between groups showed that the A/A sample contained statistically higher levels of TPH2 mRNA compared to the G/G sample (P = 0.024) or the G/A sample (P = 0.04). There was no statistical difference in levels of TPH2 mRNA expression between the G/G and G/A samples (P = 0.659). Figure 5 shows the distribution of TPH2 mRNA measurements for combined G/G and G/A samples compared to A/A samples. Although the spread of the data is large for both sets of samples, the A/A samples contain statistically significant higher levels of TPH2 mRNA compared to the combined G/G and G/A samples (P = 0.0075). C for GAPDH varied from 15 to 18.4.
Kappa-coefficient
To address the question whether mRNA levels in the pons tissue sections reflect specific expression in serotonergic neurons, rather than nonspecific background expression, we compared TPH2 mRNA levels in pons with levels in cerebellum and cortex and lymphoblasts. Again, GAPDH mRNA was used as a reference. As shown in Figure 6 , TPH2 mRNA levels were significantly higher in pons compared to cerebellum, occipital, frontal, parietal or temporal cortex and much higher than levels in lymphoblasts (ANOVA; P < 0.0001). 
Discussion
This study is the first to reveal the presence of a frequent, functional, cis-acting polymorphism in the TPH2 gene that significantly affects mRNA expression. To detect allelic differences in TPH2 mRNA expression, we developed and validated an accurate assay of AEI applicable to human autopsy brain tissues. Importantly, the functional analysis was performed in human pons, the physiologically relevant target tissue. Allelic differences in TPH2 mRNA levels likely reflect expression in serotonergic neurons in the dorsal and median raphe nuclei, which are the primary source of serotonin in forebrain. Genotyping SNPs located within the TPH2 gene identified individual SNPs and haplotypes that predict high or low levels of TPH2 mRNA expression in human pons (Figure 4) . Specifically, low levels of TPH2 mRNA expression are associated with the CTGTG combination of alleles and high levels of expression with the TAAGA combination of alleles for the SNPs rs2171363, rs4760815, rs7305115, rs6582078 and rs9325202.
As these SNPs are tightly linked ( Figure S1 ), it is not evident which SNP or SNP-combination is the 'functional' element that controls TPH2 mRNA levels. Four of these SNPs (rs2171363, rs4760815, rs6582078 and rs9325202) are located within introns and one (rs7305115) within a coding exon. Analysis of predicted changes in mRNA structure for each of these SNPs using Mfold 19 showed only small differences between alleles (A Johnson, data not shown). To investigate possible functional effects of the exonic SNP rs7305115, we exogenously expressed TPH2 mRNA of both alleles in CHO cells using cDNA expression vectors. No prominent differences in allelic expression or mRNA degradation rates were detectable between exogenously expressed TPH2 mRNAs containing the rs7305115 A-or G-allele ( Figure S3 ). This result, however, does not address possible differences in mRNA processing and maturation occurring at the level of hnRNA, since introns were absent from the cDNA constructs.
Analysis of possible effects of TPH2 SNPs on mRNA transcription and processing using the webtool PupaSNP (http://pupasnp.bioinfo.ochoa.fib.es; Conde et al. 20 ) , showed that the A-allele of rs7305115 (the minor allele) generates a consensus binding site for the serine-arginine (SR)-proteins SR35 and SRP40, splicing factors that bind exonic splicing enhancers (ESEs). 21 Exons containing a nonfunctional or partially functional ESE are often skipped during RNA splicing, 21 possibly accounting for the lower yield of mRNA from the G-allele, which appears to be the main ancestral allele (see below). Skipping of exon 7 of the TPH2 gene would result in a modified mRNA that encodes a truncated form of TPH2 due to the insertion of an in-frame stop codon (data not shown). Recent studies have shown that mRNAs containing a premature translation termination signal often undergo preferential degradation via a poorly understood mechanism termed nonsensemediated mRNA decay. 21 Thus, the G-allele of rs7305115 might be expected to produce lower levels of full length TPH2 mRNA by increasing the frequency of exon skipping. This mechanism could account for the observed AEI of TPH2 mRNA in A/G heterozygotes (Figures 1-3 ) and lower levels of TPH2 mRNA expression in G/A heterozygotes and G/G homozygotes compared to A/A homozygotes ( Figure 5 ).
To determine if aberrant TPH2 mRNAs lacking exon 7 are expressed in pons, we carried out RT-PCR amplification of TPH2 cDNA using sets of synthetic oligonucleotide primers that specifically amplify cDNA segments that contain or lack exon 7, respectively. These measurements produced two PCR products, with sizes corresponding to exon 7-containg and exon 7-deleted cDNAs, in each of the 48 samples in our collection. The predicted structures of both PCR products were confirmed by DNA sequencing. Real-time PCR measurements using primer sets specific for each mRNA showed that relative levels of the full-length and exon 7-deleted forms of TPH2 mRNA varied widely between samples (data not shown). Exon 7-deleted mRNA appears to be present at very low levels, impeding a quantitative analysis. Nevertheless, these experiments provide evidence for aberrant splicing of the TPH2 gene in the pons and suggest a possible mechanism by which the rs7305115 A-allele increases and the G-allele decreases levels of TPH2 mRNA. Our results suggest that the A-allele may yield higher mRNA levels by enhancing the efficiency of proper mRNA splicing, representing a gain-of-function.
The rs7305115 G-allele appears to be the ancestral allele, since sequences from a rhesus monkey (http:// www.hgsc.bcm.tmc.edu/projects/rmacaque/) and a chimpanzee (http://www.hgsc.bcm.tmc.edu/projects/ chimpanzee/) have G at this position. The G-allele is also present in the mouse and rat. The high frequency of the A-allele in Caucasian populations (0.33-0.41) could have resulted from a population bottleneck or random genetic drift, or by positive selection. Since the A-allele is also present at high frequency (0.29-0.39) in African populations, it dates back to early human evolution. The high accumulation of a gain-offunction polymorphism is unusual and points towards positive selection, or balanced selection. 22 The existence of positive selection would indicate that TPH2 variants significantly affect reproduction, possibly through a positive effect on mood or mental activity.
Even before the functional element(s) that control levels of TPH2 mRNA expression are identified, knowledge of marker SNPs and haplotypes that strongly predict high or low levels of TPH2 mRNA expression should be useful for association studies seeking to establish a role for TPH2 in human disease. As TPH2 encodes the enzyme that catalyzes the ratelimiting step in the synthesis of serotonin, it is plausible that differences in TPH2 mRNA expression in the range of 1.2-to 2.5-fold could contribute to disorders in which serotonin plays a role. Moreover, the high frequencies of the implicated SNPs and haplotypes suggest a possible role in brain disorders that affect a significant portion of the population, such as major depression, which has a life-time prevalence of about 16%. 23 Since the discovery of the TPH2 gene in 2003, 4 14 published studies have examined possible associations between TPH2 SNPs and various mental disorders including major depression, 17, 24, 25 bipolar disorder, 26 anxiety disorders, 27, 28 attention-deficit/ hyperactivity disorder (ADHD), 29, 30 autism 31 or suicidal behavior. 17, [32] [33] [34] [35] [36] The results of these studies have been mixed, with nine studies showing weak, but statistically significant associations between one or more TPH2 SNP and a specific mental disorder, 17, [24] [25] [26] [27] [29] [30] [31] [32] and five showing no significant associations. 28, [33] [34] [35] [36] Most of the studies reporting negative results failed to detect statistically significant associations for SNPs in the putative promoter region or intronic SNPs in the 5 0 -end of the gene. These regions are also not associated with allelic mRNA expression observed in our study.
One of the nine positive studies reported an association between a rare loss-of-function mutation (G1463A; R441H) in TPH2 exon 9 and treatmentresistant depression, 25 but this was not replicated in five subsequent studies. 8, [37] [38] [39] [40] Among the remaining eight studies reporting an association between TPH2 SNP alleles and a mental disorder, four found statistically significant associations for SNPs within the region comprising introns 5-8.
Zill et al. 24 reported a statistically significant (P = 0.012, after Bonferroni correction) difference in allele frequencies for an intron 5 SNP (rs1386494) between Caucasian patients (n = 300) with major depression and ethnically matched controls (n = 265), with lower frequency of the A-allele in patients (A/ G = 0.14/0.86) compared to controls (A/G = 0.21/0.79). (See Figure S1 in Supplementary materials for the locations of TPH2 SNPs discussed in this section.) Statistically significant associations were also demonstrated between major depression and three haplotypes comprising alleles of 10 SNPs located within introns 5 and 6. In a second study, 32 the same group reported a statistically significant association between rs1386494 and completed suicides (n = 263) vs ethnically matched controls (n = 266), again finding higher levels of the G-allele in suicide victims (A/G = 0.14/ 0.86) and the A-allele in controls (A/G = 0.21/0.79). Four 10-SNP haplotypes (different from those identified in the depression study) showed correlations with suicide, but were not statistically significant after correction for multiple testing.
A study by Zhou et al. 17 examined associations between 15 TPH2 SNPs and: (1) anxiety/depression, (2) suicide attempt, and (3) major depression in four populations. Weak associations between these disorders and individual SNPs located within the introns 5-8 segment of TPH2 were observed. The SNPs showing associations, however, varied between disorders and between populations, and none remained significant after correction for multiple testing. Haplotype analysis revealed the presence of high-frequency 'yin' and 'yang' haplotypes, with complementary patterns of major and minor alleles. Again, weak associations (significant only in the absence of corrections for multiple testing) were observed, with a trend towards association of the yin-haplotype with anxiety/depression and suicide, and possible protection from these disorders by the yang-haplotype. The yin-haplotype was also associated with lower cerebral spinal fluid levels of the serotonin metabolite 5-hydroxyindolacetic acid in nonmedicated controls who were free of psychiatric disorders. Significantly, the yin-haplotype includes the G-allele of rs7305115, which we showed in this study to associate with low levels of TPH2 mRNA expression. The yang-haplotype includes the A-allele of rs7305115.
A study by Harvey et al. 26 uncovered a weak association between bipolar disorder and haplotypes comprising alleles of SNPs located within the exons 7-9 segment of the TPH2 gene. Mossner et al. 27 described an association between obsessive-compulsive disorder (OCD) and the G-C haplotype for rs4570625 and rs4565946, SNPs located in the putative regulatory region and intron 2, respectively. Walitza et al. 29 described a weak association between regulatory region SNPs (rs4570625 and rs11178997) and attention-deficit hyperactivity disorder (ADHD). Sheehan et al. 30 detected a statistically significant association between the T-allele of rs1843809 (intron 5) and ADHD in transmission disequilibrium analysis of 179 Irish families. Finally, a recent study by Coon et al. 31 reported statistically significant associations between autism and TPH2 SNPs in introns 1 and 4 (rs4341581 and rs11179000).
Three recent studies have detected associations between a SNP in the putative TPH2 regulatory promoter region (rs4570625; G/T) and amygdala activity 41, 42 or 'emotional processing'. 43 Brown et al. 41 used functional magnetic resonance imaging (fMRI) to detect greater bilateral dorsal amygdala reactivity to fearful stimuli in individuals carrying the T-allele (T/T or T/G) compared to G/G homozygotes. An independent fMRI study by Canli et al. 42 observed increased responses in both the right and left amydala of T-allele carriers viewing fearful, happy or sad faces compared to faces with neutral expression. Hermann et al. 43 detected a tendency in T-allele carriers towards increased event-related potentials (ERPs) in electroencephalograms recorded 240 ms after viewing pictures with high emotional content. An additive effect was detected in individuals carrying both the T-allele and the 'short' promoter allele 44, 45 of the serotonin transporter (SERT) gene.
As described above, we observed a weak, but positive, correlation between rs4570625 heterozygo sity and TPH2 mRNA AEI in adult pons (Kappacoefficient = 0.311; P = 0.053; Figure 4 and Table S2 ). These data suggest that rs4570625 does not control TPH2 mRNA expression, but may be in partial LD with a functional polymorphism that does. In fact, our genotyping results ( Figure S2 ) predict that rs4570625 is in partial LD with SNPs (rs2171363, rs4760815, rs7305115, and rs6582078) that highly correlate with TPH2 mRNA AEI. These observations suggest that reanalysis of the imaging and electroencephalography data in the above studies might show stronger correlations with rs7305115 compared to rs4570625. Alternatively, it is possible that rs4570625 (or a closely linked polymorphism in the promoter region) directly regulates TPH2 mRNA expression specifically during times of emotional stress and/or during brain development. As serotonin has been shown to play a role in the development of the brain, 46, 47 it is possible that differential expression of THP2 at specific stages of brain development may differentially influence the development of neuronal circuits that control amygdala activity in the adult. This interesting possibility remains to be examined.
Taken together, the studies described above provide preliminary evidence for a role for TPH2 alleles in several mental disorders and processing of emotional stimuli. None of the studies, however, identified functional alleles, and thus do not provide mechanistic explanations for the observed associations. The fact that many of the above studies identified different associating SNPs suggests that the studies may lack sufficient power to reliably detect associations for SNPs that are in partial linkage with a functional polymorphism within the TPH2 gene. We suspect that larger studies would show stronger associations for most SNPs in the region, with the strongest association observed for the functional polymorphism.
Future studies examining the potential associations between TPH2 and mental disorders should consider the following points: (1) The contribution of TPH2 to a complex disease may be small, and therefore large numbers of individuals may need to be examined to observe contributions of specific alleles. (2) As previously shown for SERT promoter polymorphisms, 48 stronger associations may be detected when 'environmental' factors, such as a history of stressful life-events, are taken into consideration. (3) Stronger associations may also be observed with endophenotypes of a mental illness compared to the illness per se. For example, meta-analysis has shown SERT promoter polymorphisms to correlate more highly with 'neuroticism,' a personality trait highly associated with depression, than with depression itself. 49 (4) Additional cis-acting elements may need to be taken into consideration. In this study, we scored heterozygous SNPs as being positively correlated with AEI, if the measured AEI was > 1.2. Perhaps stronger associations with mental illness could be detected using combinations of SNPs that predict higher levels of AEI, for example, > 2. (5) If the gain-of-function we have observed for the rs7305115 A-allele indeed were to have phenotypic penetrance in mental disorders (in this case, possibly a protective effect), this may only become apparent in combination with variants in one or more additional genes that functionally interact with TPH2. AEI measurements, as described here for TPH2, have already revealed the presence of frequent functional polymorphisms in other genes previously implicated in mental disorders, including the m-opiate (OPRM1), 14 monoamine oxidase A (MAOA) 50 and the type 2-dopamine receptor (DRD2) (manuscript in preparation), so that accounting for interactions among multiple genes could reveal significant impact on mental disorders, or variation in normal human behavior.
Clearly we are only at the beginning of the process of elucidating the genetic basis of mental illness. As for other complex diseases, multiple genes are likely to play a role. Identifying genetic variants that modify, or strongly predict, levels of mRNA expression for candidate genes provides a rich source of markers with high 'prior-probability' for association studies. In particular, using allele-specific mRNA expression as an intermediate phenotype is an efficient method for identifying 'functional' polymorphisms that contribute to the complex phenotypes associated with mental illness or response to therapeutic drugs.
